Form Type: 8-K Current Report filed by Eli Lilly and Company on February 4, 2026 Item 2.02 - Results of Operations and Financial Condition: The filing reports results of operations and financial condition for the company Item 9.01 - Financial Statements and Exhibits: The filing includes financial statements and exhibits as supporting documentation Company Information: Eli Lilly and Company,…

Our analysis rates this filing BULLISH. This 8-K filing represents a standard quarterly earnings announcement for Eli Lilly and Company with no material negative disclosures. The absence of risk factors, litigation, regulatory issues, executive changes, or operational concerns indicates stable…

Concern level: LOW (1.5/10). Key factors: No material negative events identified in filing; No new risks disclosed; No litigation, regulatory actions, or operational issues mentioned.

Notable risk changes: This is a routine 8-K filing disclosing Q4 2025 and full-year 2025 financial results - no material negative events identified; Filing contains only standard earnings announcement with press release (Exhibit 99.1) - no risk disclosures, litigation, regulatory actions, or operational issues mentioned; No material changes to business operations, covenant violations, executive departures, product…

The model predicts LLY will underperform the S&P 500 by about 0.0% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.